What STADA Bulgaria does

STADA Bulgaria EOOD is a wholly-owned Bulgarian subsidiary of the German pharmaceutical group STADA Arzneimittel AG, focused on distributing the parent's generics, OTC consumer health, and biosimilar portfolio to Bulgarian pharmacy retail and hospital channels. The product range spans established OTC brands (Nizoral, Sinulan, Cetebe, Proenzi, Urinal, Prostenal, Orofar, Profilakt), generics, and specialty/biosimilar products (bevacizumab, epoetin zeta, teriparatide, pegfilgrastim, Lecigon, Movymia), with the portfolio expanded materially by the 2020 Walmark acquisition and the end-2021 Sanofi distribution agreement covering approximately 50 OTC brands across around 20 European countries.

The entity functions as a commercial distribution and marketing operation rather than a manufacturing or R&D site; technical capability rests on regulatory compliance for biosimilar and generic registrations, pharmacy and hospital sales force coverage, and brand stewardship for legacy consumer health franchises. Manufacturing scale for the broader CEE portfolio sits at parent-group level, exemplified by the EUR 50 million investment at the Turda, Romania facility announced in January 2022.

Revenue mechanics are conventional pharma distribution: the company purchases from STADA group manufacturing and partners (including Sanofi) and sells to fragmented Bulgarian pharmacy chains, independent pharmacies, and hospital buyers. Bulgarian-entity revenue is not separately disclosed in available materials; parent group revenue was EUR 3.01 billion in 2020. The Bulgarian team scaled materially from fewer than 10 employees to approximately 110 by 2022,, indicating rapid commercial build-out in support of the expanded portfolio.

Name

STADA Bulgaria

Legal name

STADA Bulgaria EOOD

Website

https://stada.bg

Company type

Private

Founded year

1895

Operating status

Operating

Headcount range

51–100 employees

Short description

STADA Bulgaria EOOD is a wholly-owned subsidiary of Germany's STADA Arzneimittel AG that distributes the parent's generics, OTC consumer health brands, and biosimilar portfolio to Bulgarian pharmacy retail and hospital channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (4242), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

akta.pro secondary industries

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF), Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief) (CRADAMAJ)

Keywords

• Generic pharmaceuticals
• Over-the-counter medicines
• Biosimilar medicines
• Consumer health products
• Pharmaceutical distribution

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D, Others

Revenue model

1. Generic Pharmaceuticals: Sale of high-quality generic pharmaceutical products, both prescription and OTC, at affordable prices. Products cover therapeutic areas including cardiology, neurology, allergology, and antibiotics.
2. OTC / Consumer Health Products: Sale of branded OTC products including Nizoral, Sinulan, Orofar, Proenzi, Cetebe, Urinal, Prostenal, and others through pharmacy retail channels.
3. Specialized / Biosimilar Products: Sale of specialized pharmaceutical products including biosimilar medicines such as bevacizumab, epoetin zeta, teriparatide, and pegfilgrastim, primarily for oncology, immunology, and osteoporosis treatment.
4. Sanofi Distribution Rights: Distribution rights for Sanofi OTC products acquired in end of 2021, covering approximately 50 established OTC brands in 20 European countries including Bulgaria.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

STADA Bulgaria distributes and sells a three-pillar pharmaceutical portfolio in Bulgaria: (1) generic prescription medicines focused on cardiology, neurology, allergology, and antibiotics; (2) branded OTC consumer health products (Nizoral, Sinulan, Cetebe, Orofar, Proenzi, Urinal, Prostenal, Ginko Prim, Profilakt) covering dermatology, respiratory, vitamins, joint, urinary, and prostate health; and (3) specialty biosimilars such as bevacizumab, epoetin zeta, teriparatide, pegfilgrastim, plus specialized products like Lecigon (Parkinson's) and Movymia (osteoporosis). The entity also distributes selected Sanofi OTC brands under a 2021 distribution agreement. Products reach patients primarily through Bulgarian pharmacy retail networks and hospital/specialty pharmacies.

Product overview

STADA Bulgaria is a pharmaceutical company offering a diversified portfolio across three strategic pillars: generic medicines, specialty pharmaceutical products (biosimilars), and consumer health OTC products. The OTC portfolio includes leading brands such as Nizoral® (medicated dandruff shampoo), Sinulan® (respiratory health), Orofar® (throat care), Cetebe® (Vitamin C with Time Pearl™ technology), Proenzi® (joint health), Urinal® (urinary tract health), Prostenal® (prostate health), and Profilakt® (probiotics). The specialty segment includes biosimilars like bevacizumab, epoetin zeta, teriparatide, and pegfilgrastim, as well as specialized products Lecigon® for Parkinson's and Movymia® for osteoporosis. Generic prescription medicines focus primarily on cardiology, neurology, allergology, and antibiotics. The company also distributes selected Sanofi OTC brands including Allegra, Bisolvon, Dulcolax, and Essentiale Forte N.

Differentiator

Problem solved

Functional benefit

Brands

• Nizoral®: Medicated shampoo for treating dandruff; contains ketoconazole, targets the fungus causing dandruff, relieves itching and scalp redness with visible results after 2 weeks.
• Sinulan®
• Cetebe®
• Prostenal®
• Orofar®
• Proenzi®
• Urinal®
• Ginko Prim®
• Profilakt®

Products and services

• Nizoral® (Низорал®) Medicated anti-dandruff shampoo containing ketoconazole that fights the fungus causing dandruff, relieves scalp itching and redness, with visible results after 2 weeks. Sold OTC through Bulgarian pharmacies.
• Sinulan® (Синулан®) Product line for respiratory and sinus health including Sinulan Forte, Sinulan Express, Sinulan Duo Forte, Sinulan Forte Junior, and Sinulan Express Junior. Addresses rhinitis, sinusitis, nasal congestion, and supports upper and lower respiratory tract function. Sold OTC through Bulgarian pharmacies.
• Cetebe® (Цетебе®) Vitamin C product line using the proprietary Cetebe Time Pearl™ time-release technology that enables gradual and sustained release of vitamin C. Available in various formats and combinations including high-dose pure Vitamin C. Sold OTC through Bulgarian pharmacies.
• Orofar® (Орофар®) Throat health product line including OTC medicines with benzoxonium chloride and lidocaine hydrochloride, plus dietary supplements with phytoextracts (chamomile, sage, thyme, marshmallow, peppermint). Available as lozenges and spray. Sold OTC through Bulgarian pharmacies.
• Proenzi® (Проензи®) Joint health product line including Proenzi Rapid (glucosamine, chondroitin, type II collagen, Vitamin C, Boswellia serrata), Proenzi Intensive (concentrated formula for joint health), and Proenzi Cream (massage cream for muscle and joint relief). Sold OTC through Bulgarian pharmacies.
• Urinal® (Уринал®) Urinary tract health product line including Urinal Akut® (acute symptoms), Urinal Nefro® (daily support), Urinal Syrup® (pediatric formulation), Urinal Capsules®, and Urinal Drink® (sachets). Sold OTC through Bulgarian pharmacies.
• Prostenal® (Простенал®) Prostate health products including Prostenal Perfect (normal urinary tract function and male potency support) and Prostenal Night (supports normal urination and natural sleep). Sold OTC through Bulgarian pharmacies.
• Ginko Prim® (Гинко Прим®) Ginkgo biloba dietary supplement supporting brain and limb blood circulation, memory, concentration, and brain functions. Sold OTC through Bulgarian pharmacies.
• Profilakt® (Профилакт®) Probiotic products including Profilakt Perfect that protects and restores probiotic structure from the first day of antibiotic treatment. Sold OTC through Bulgarian pharmacies.
• Generic Medicines High-quality and affordable generic prescription medications covering therapeutic areas including cardiology, neurology, allergology, and antibiotics. Sold through Bulgarian pharmacy channels.
• Biosimilars Specialty pharmaceutical products including biosimilars epoetin zeta, teriparatide, bevacizumab, and pegfilgrastim. Distributed to hospital pharmacies and specialty treatment centers for oncology, immunology, and osteoporosis treatment.
• Lecigon® Specialized pharmaceutical product indicated for the treatment of advanced-stage Parkinson's disease. Distributed through Bulgarian hospital and specialty pharmacies.
• Movymia® Biosimilar medication for the treatment of osteoporosis. Distributed through Bulgarian hospital and specialty pharmacies.
• Sanofi OTC Portfolio Distribution Distribution rights for Sanofi's OTC product portfolio under the December 2021 distribution agreement. Includes approximately 50 established OTC brands including Allegra, Bisolvon, Dulcolax, and Essentiale Forte N sold across 20 European countries including Bulgaria.

Quantifiable outcome

• STADA achieved 5% adjusted sales growth to 1.51 billion EUR in H1 2021, outpacing the European pharmaceutical market which declined by -1.8%.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and major.

• SanoficoreChannel Partner/ Reseller/ Distributor · 1 December 2021In late 2021, STADA and Sanofi signed a distribution agreement giving STADA full rights to distribute Sanofi's OTC product portfolio. The agreement covers approximately 50 established OTC brands including Allegra, Bisolvon, Dulcolax, and Essentiale Forte N, across 20 European countries including Bulgaria, the Nordic countries, the Netherlands, Ireland, the Baltic states, and Balkan countries. Additionally, STADA agreed to acquire 16 brands from Sanofi (including Silomat, Mitosyl, and Frubiase) in key European markets.
• Calliditas (Sweden)coreStrategic or Co-development Partner · 1 August 2021STADA entered into a partnership with Swedish biotech firm Calliditas focused on the registration and commercialization of the first approved treatment in the EU for chronic autoimmune kidney disease IgA nephropathy (IgAN). The partnership leverages STADA's regulatory and commercial capabilities in Europe.
• mAbxience (Spain)coreStrategic or Co-development Partner · 1 March 2021STADA partnered with Spanish biotech company mAbxience for the development and marketing of biosimilar bevacizumab in approximately 40 European countries including all EU member states. mAbxience has extensive experience in supplying bevacizumab to markets including Latin America since 2016. STADA holds marketing and sales rights under the agreement.
• WalmarkcoreStrategic or Co-development Partner · 1 March 2020STADA Group acquired Walmark in March 2020, a key acquisition that strengthened STADA's OTC brand portfolio in Central and Eastern Europe including Bulgaria. The successful development of key OTC brands on the Bulgarian market cemented the company's position as a market leader in the OTC segment.
• Takeda (Russia and CIS)majorStrategic or Co-development Partner · 1 January 2020STADA acquired Takeda's portfolio in Russia and the CIS region in 2020, which included 15 consumer health brands. This acquisition helped establish STADA as a leading OTC company in Russia and strengthened its position in Eastern European markets.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• KRKA: Slovenian-headquartered generics and OTC manufacturer with strong Central and Eastern European footprint including Bulgaria. Closely comparable business model with prescription generics, OTC brands, and pharmacy-led sales force.
• Sandoz (Bulgaria): Sandoz, the Novartis generics and biosimilars division, sells prescription generics and biosimilars in Bulgaria through pharmacy and hospital channels. Directly comparable on generic/biosimilar portfolio breadth and CEE distribution approach.
• Egis Pharmaceuticals: Hungarian generics and specialty pharmaceutical producer with established CEE footprint including Bulgaria. Comparable on generics portfolio across cardiovascular, neurology, and other therapeutic areas distributed through Bulgarian pharmacies.
• Zentiva: Pan-European generics and OTC company headquartered in Prague with significant Bulgarian operations across prescription generics and consumer health. Direct peer given overlapping CEE generics and OTC focus and similar pharmacy-channel go-to-market.
• Alvogen (Bulgaria): US-based generics group with a strong Central and Eastern European footprint and active Bulgarian commercial presence in prescription generics. Comparable generics portfolio and CEE-focused distribution model.
• Teva Pharmaceutical Industries (Bulgaria): Global leader in generics with established Bulgarian operations offering generic prescription medicines and select OTC products through pharmacy channels. Directly comparable to STADA Bulgaria on generic/OTC portfolio mix and pharmacy-led distribution model.

Emerging players

• Walmark (STADA Group): Central European OTC and supplement brand portfolio acquired by STADA Group in March 2020 and now part of the same group as STADA Bulgaria. Strongly comparable OTC consumer health portfolio (vitamins, joint care, urinary health) overlapping with brands such as Proenzi, Urinal, and Prostenal.

Broad incumbents

• Bayer Bulgaria (Consumer Health): Bayer's Consumer Health division markets major OTC brands (e.g., Bepanthen, Aspirin, Iberogast) in Bulgaria through pharmacies. Comparable OTC consumer health focus but as part of a much broader pharma/agritech incumbent.
• Sanofi Bulgaria (Consumer Healthcare): Global pharma incumbent with a substantial OTC portfolio (Allegra, Dulcolax, Essentiale Forte) sold in Bulgaria, and now a distribution partner of STADA. Comparable OTC consumer health presence but as a much larger diversified pharma group.

Others

• GlaxoSmithKline (Bulgaria) - Haleon/Consumer Healthcare: GSK/Haleon's consumer healthcare arm markets leading OTC brands (e.g., Coldrex, Panadol, Voltaren) in Bulgaria. Comparable consumer health/OTC focus but operates as a large diversified global incumbent rather than a generics-led specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/stada-bulgaria

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STADA Bulgaria